{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:05:09Z","timestamp":1743134709710,"version":"3.40.3"},"reference-count":15,"publisher":"Termedia Sp. z.o.o.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anaesthesiol Intensive Ther"],"abstract":"Introduction<\/jats:title>Malignant hyperthermia (MH) is a life-threatening syndrome caused by sudden skeletal muscle hypermetabolism in response to inhalation anaesthetics and depolarising relaxants. The estimated incidence of MH is between 1 : 10,000 and 1 : 250,000 anaesthetic procedures. In Poland the incidence of MH is unknown. Dantrolene is imported as a life-saving drug and temporally authorised for sale. The aim of the study is to assess the incidence of MH and access to dantrolene in the Mazovia Province.<\/jats:p><\/jats:sec>Methods<\/jats:title>Anonymous questionnaires were sent to anaesthesia departments in the Mazovia Province after prior contact by phone and e-mail. The survey was approved by the local ethical review board.<\/jats:p><\/jats:sec>Results<\/jats:title>Completed surveys were received from 60 respondents which represents 72% of anaesthesiology departments in Mazovia. In the last 5 years there have been 4 episodes of MH in the Mazovia Province. Three patients survived the MH crisis. In a centre that did not have access to dantrolene, the patient died. Dantrolene is found only in 11 (18.3%) anaesthesiology departments in Mazovia. Only 6 (10%) hospitals are able to administer dantrolene within 5 minutes of suspecting MH crisis, while 5 centres may receive it after a few days. Only 38% of units have an algorithm for dealing with MH crisis in the operating theatres.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>MH is rare, but if untreated, it can be fatal. Therefore prompt diagnosis and treatment are crucial to avoid fatal outcome. Every centre using inhalational anaesthetics and\/or succinylcholine should have dantrolene. To ensure the safety of our patients, we must be better prepared.<\/jats:p><\/jats:sec>","DOI":"10.5114\/ait.2022.115348","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:39:36Z","timestamp":1651822776000},"page":"99-102","source":"Crossref","is-referenced-by-count":2,"title":["Malignant hyperthermia in Mazovia Province \u2013 are we adequately prepared?"],"prefix":"10.5114","volume":"54","author":[{"given":"Agnieszka","family":"Cieniewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Trzebicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"ref-1376785","doi-asserted-by":"publisher","DOI":"10.5114\/ait.2019.87646"},{"key":"ref-1376786","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0310-1"},{"key":"ref-1376787","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318167aee2"},{"key":"ref-1376788","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318200197d"},{"key":"ref-1376789","article-title":"23th Annual Meeting of the European Malignant Hyperthermia Group in Leipzig","author":"Mayzner-Zawadzka E","year":"2004","unstructured":"Mayzner-Zawadzka E. Current status of malignant hyperthermia in Poland. 23th Annual Meeting of the European Malignant Hyperthermia Group in Leipzig 2004."},{"key":"ref-1376790","unstructured":"Biuletyn statystyczny 03\/2021. Available at: www.stat.gov.pl.","article-title":"Biuletyn statystyczny 03\/2021"},{"key":"ref-1376791","unstructured":"Zdrowie i Ochrona Zdrowia w 2019 roku. Available at: https:\/\/stat.gov.pl\/obszary-tematyczne\/zdrowie\/zdrowie\/zdrowie-i-ochrona-zdrowia-w-2019-roku,1,10.html#.","article-title":"Zdrowie i Ochrona Zdrowia w 2019 roku"},{"key":"ref-1376792","unstructured":"Ustawa z dnia 6 wrze\u015bnia 2001 r. Prawo farmaceutyczne. Available at: http:\/\/isap.sejm.gov.pl\/isap.nsf\/download.xsp\/WDU20011261381\/U\/D20011381Lj.pdf (Accessed: 25.06.2021).","article-title":"Ustawa z dnia 6 wrze\u015bnia 2001 r"},{"key":"ref-1376793","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181ac1548"},{"key":"ref-1376794","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.04.089"},{"key":"ref-1376795","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeq243"},{"key":"ref-1376796","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S47632"},{"key":"ref-1376797","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000257"},{"key":"ref-1376798","first-page":"33","article-title":"Oficyna Wydawnicza UNIMED, Jaworzno","author":"Orlewska M","year":"2002","unstructured":"Orlewska M, Czech M. S\u0142ownik farmakoekonomiczny. Oficyna Wydawnicza UNIMED, Jaworzno 2002; p. 33."},{"key":"ref-1376799","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e318298867a"}],"container-title":["Anaesthesiology Intensive Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.ait-journal.com\/pdf-141916-121789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ait-journal.com\/pdf-141916-121789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T10:40:03Z","timestamp":1743072003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ait-journal.com\/Malignant-hyperthermia-in-Mazovia-Province-are-we-adequately-prepared-,141916,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"alternative-id":["141916"],"URL":"https:\/\/doi.org\/10.5114\/ait.2022.115348","relation":{},"ISSN":["1642-5758","1731-2531"],"issn-type":[{"type":"print","value":"1642-5758"},{"type":"electronic","value":"1731-2531"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}